KDR and neoplasm: Sunitinib (SU11248; Sutent ®) was developed in 2003 as an orally bioavailable ATP-competitive inhibitor of VEGFR, PDGFR, KIT, and FLT3 receptor tyrosine kinases, and effectively inhibits tumor growth of multiple cancer cell types, namely breast, NSCLC, colon cancer, glioma, and melanoma when administered daily as a single agent (244–247).